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Adoptive immunotherapy has proven efficiency in
patients suffering from malignancies. However, the qual-
ity of in vitro generated tumor antigen-specific T cells
which can be used for such therapies is limited. Therefore,
methods have to be developed in order to increase
potency of these tumor antigen-specific T lymphocytes.
One possibility arises from the modification of glycopro-
teins such as the T cell receptor (TCR) or CD8. By their size
and charge, sugar chains of these molecules play a role in
the interaction of a T cell with the major histocompatibil-
ity complex (MHC). It is also reported that glycosylation
decreases mobility of cell surface molecules by cross link-
ing to carbohydrate binding proteins (so called lectins,
e.g. Galectin-3). The resulting molecular lattice constrains
TCR and CD8 clustering. Deglycosylation of the TCR and
CD8 might be a possibility in order to increase mobility
of the TCR or CD8 and to augment signalling strength.
Unspecific global O- and N-deglycosylation were com-
pared as well as a specific removal of selective glycosyla-
tion motives in defined proteins as the TCR.
For exogenous deglycosylation, T cells were treated with
neuraminidase, which removes sialic acids at the end of
sugar chains. This resulted in a better communication of
the O-glycosylated CD8 with the MHC I molecule which
was demonstrated by an increased specific tetramer-bind-
ing. Surprisingly, the ability to kill tumor cells was not
increased. To inhibit the interaction of N-linked sugars of
the TCR with Galectin-3 and so to increase mobility of the
TCR, T cells were treated with lactose, which competes
with the Galectin-binding sugars for Galectin-3. However,
lactose-treatment did also not ameliorate target cell lysis.
Thus, T cell deglycosylation could increase tetramer-bind-
ing, but this was not translated into a better T cell activity.
We assumed, that other surface molecules which are
important for signalling were negatively affected by these
treatments. As consequence, we silenced N-glycosylation
motives in the TCR molecule itself by point mutation.
Wild-type and mutant TCRs were transduced into human
T cells or the murine T cell hybridoma 58a-b- by retroviral
gene transfer. Efficacy of TCR deglycosylation was ascer-
tained by western blot analysis. Removing one or two
defined sugar chains increased antigen-specific cytokine
secretion. Deletion of three or more glycosylation sites
impaired T cell function.
In summary, T cell deglycosylation is a sensitive mecha-
nism. Deletion of defined glycosylation motives within a
TCR is an efficient tool to increase signalling strength of a
T cell.
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